Introduction: Interleukin-5 (IL-5) is the principal cytokine regulating eosinophil growth, differentiation, activation, and expression. It is a specific target of mepolizumab, an anti-IL-5 monoclonal antibody used in the treatment of severe eosinophilic asthma. This new drug can improve symptoms, reduce asthma exacerbations and steroid use. Few data are available on its efficacy for nasal symptoms. Objective: To describe the all-round clinical impact of mepolizumab in a real-life setting, evaluating the efficacy and safety of the drug in severe eosinophilic asthma patients. Population and Methods: We retrospectively collected the clinical and functional data on 27 patients (16 males) affected with severe eosinophilic asthma, diagnosed at the Siena Regional Referral Centre and monitored for 6 months. Clinical, immunological, and functional data at baseline and follow-up were entered in a database together with comorbidities, number of exacerbations, steroid treatment, multiple-flow exhaled nitric oxide, and validated questionnaires. Results: A significant reduction in asthma exacerbations was observed in all patients after 6 months of the biological therapy (p = 0.0009), and 4/6 patients discontinued chronic oral steroids. A significant improvement in ACT, FEV1, SNOT22, and alveolar nitric oxide was observed after 1 month of mepolizumab (p = 0.003, p = 0.007, p = 0.047, and p = 0.019, respectively) and maintained after 6 months of treatment. After 6 months, FeNO 50 was reduced as well (p = 0.030). Mepolizumab was very well tolerated, and no major side effects were observed. Conclusions: Our study suggests that mepolizumab is effective in improving control of asthma, lung function parameters, exhaled biomarkers, and nasal symptoms in patients with severe eosinophilic asthma.
Int Arch Allergy Immunol

中文翻译：

---

在实际生活中对Mepolizumab有效性的综合评估。

简介：白介素5（IL-5）是调节嗜酸性粒细胞生长，分化，激活和表达的主要细胞因子。它是美波珠单抗的特异靶标，美波珠单抗是一种用于治疗严重嗜酸性粒细胞性哮喘的抗IL-5单克隆抗体。这种新药可以改善症状，减少哮喘发作和类固醇的使用。关于鼻部症状的功效尚无可用数据。目的：描述美泊珠单抗在现实生活中的全方位临床影响，评估该药物在重度嗜酸性粒细胞性哮喘患者中的疗效和安全性。人口与方法：我们回顾了在锡耶纳地区转诊中心诊断并监测了6个月的27例严重嗜酸性粒细胞性哮喘患者的临床和功能数据。将基线和随访时的临床，免疫学和功能数据以及合并症，病情加重，类固醇治疗，多流呼出气一氧化氮和经过验证的问卷一起输入数据库。结果：在进行生物治疗6个月后，所有患者的哮喘急性发作率均明显降低（p = 0.0009），并且有4/6例患者停用了慢性口服类固醇。美泊利单抗治疗1个月后，观察到ACT，FEV1，SNOT22和肺泡一氧化氮的显着改善（p = 0.003，p = 0.007，p = 0.047和p = 0.019），并在治疗6个月后保持不变。6个月后，FeNO 50也降低（p = 0.030）。美泊珠单抗耐受性非常好，未观察到主要副作用。结论：我们的研究表明美泊利珠单抗可有效改善严重嗜酸性粒细胞性哮喘患者的哮喘控制，肺功能参数，呼出的生物标志物和鼻部症状。
Int Arch过敏免疫